Initial Treatments for Newly Diagnosed Colorectal Cancer

Video

There are many considerations when deciding on a treatment plan for patients with colorectal cancer (CRC), says Cathy Eng, MD. Knowledge of the disease stage is imperative, as there are limited therapies that are available in the early disease stages, which differ from those used in the metastatic setting. Molecular marker analyses are often utilized more in metastatic disease, where two biologic agents are typically given in combination with chemotherapy, based upon the results of a RAS mutation analysis.

There are advantages and disadvantages associated with all CRC treatments, making patient education critical, says Eng. When explaining the intravenous options to patients, it is helpful to also describe the factors affecting the drug’s administration and the potential impact on the patient’s quality of life. For example, an implantable catheter is inserted underneath the skin and does not limit the patient too much with regards to what he or she can do while at home, explains Eng, although patients must return to the hospital for catheter removal.

It is important to offer the patient choices, states John L. Marshall, MD. One approach is to describe the pump that would be used for a particular chemotherapy treatment, noting all of the factors associated with its use. Some patients are more comfortable with the pump, while others will prefer an oral regimen.

Related Videos
In this second episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, explain the challenges faced with preventing or detecting these cancers early and the understanding that is needed to develop effective early detection methods and move the needle forward.
In this first episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss the potential for early detection multiomic assays and the work that still needs to be done to encourage their widespread use.
Ilyas Sahin, MD
A panel of 6 experts on colorectal cancer
A panel of 6 experts on colorectal cancer
A panel of 4 experts on colorectal cancer
A panel of 4 experts on colorectal cancer
A panel of 6 experts on colorectal cancer
A panel of 6 experts on colorectal cancer
A panel of 4 experts on colorectal cancer